Abstract Introduction: Cancer incidence and mortality estimates for 25 cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for the European Union (EU-27) for 2012. Methods: We used statistical models to estimate national incidence and mortality rates in 2012 from recently-published data, predicting incidence and mortality rates for the year 2012 from recent trends, wherever possible. The estimated rates in 2012 were applied to the corresponding population estimates to obtain the estimated numbers of new cancer cases and deaths in Europe in 2012. Results: There were an estimated 3.45 million new cases of cancer (excluding non-melanoma skin cancer) and 1.75 million deaths from cancer in Europe in 2012. The most common cancer sites were cancers of the female breast (464,000 cases), followed by colorectal (447,000), prostate (417,000) and lung (410,000). These four cancers represent half of the overall burden of cancer in Europe. The most common causes of death from cancer were cancers of the lung (353,000 deaths), colorectal (215,000), breast (131,000) and stomach (107,000). In the European Union, the estimated numbers of new cases of cancer were approximately 1.4 million 0959-8049 Ó 2013 Elsevier Ltd. http://dx
Introduction
Up-to-date cancer incidence and mortality data in Europe are a key resource in both planning and assessing the impact of cancer control programmes at the country and regional level. Europe carries a significant load of the global burden, with one quarter of the global burden of cancer observed in Europe in 2008 despite a total population that comprises one-ninth of the world's population.
1, 2 The International Agency for Research on Cancer (IARC), through its programmes of collaboration with population-based cancer registries in Europe, members of the European Network of Cancer Registries (ENCR, http://www.encr.com.fr/) has provided estimates of cancer burden at the European and European Union (EU) member state level over the last 25 years. [3] [4] [5] [6] [7] [8] In this paper, we provide estimates of the incidence of, and the mortality from cancer for 25 sites in 40 European countries in 2012, using the most recently available data. The reported estimates are based on the latest incidence data provided by the ENCR member registries, the World Health Organisation (WHO) mortality database 9 and UN population estimates. 2 The results are also presented for four areas as defined by the UN (Eastern, Northern, Southern and Western Europe), 2 and the European Union 27 Member States (EU-27). The complete set of estimates is available through the European Cancer Observatory (ECO) website (http://eco.iarc.fr). 10 .
Data sources and methods
Cancer incidence and mortality for 2012 by sex and 16 age groups (0-4, 5-9,. . ., 70-74, 75 and over) are estimated for each of the 39 European countries defined by the United Nations 2 and Cyprus. Results are presented for the following cancer sites as defined by the 10th edition of the International Classification of Diseases (ICD-10) 11 : lip, oral cavity and pharynx (ICD-10 C00-14), oesophagus (C15), stomach (C16), colorectal (including anus C18-21), liver (C22), gallbladder (C23-24), pancreas (C25), larynx (C32), lung (including trachea, C33-34), melanoma of skin (C43), female breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), kidney (including renal pelvis and ureter, C64-66), bladder (C67), brain and central nervous system (C70-72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-85, C96), multiple myeloma (C88 + C90), leukaemia (C91-95) and all cancers combined, excluding non-melanoma skin cancer (C00-96, except C44). This last category was calculated by summing the estimated counts for each individual cancer site, and the corresponding estimate of the residual category "other and unspecified cancers". No attempt was made to estimate incidence and mortality from non-melanoma skin cancer given the non-systematic registration of these cases in most cancer registries.
Development of the estimates
The methods used to estimate country-specific incidence and mortality rates for 2012 are based on previous work, 8 and involve projections of the most recent national rates available prior to 2012. For countries with fifteen or more years of recent incidence or mortality data available, corresponding rates for 2012 were predicted using the NORDPRED program based on age-period-cohort modelling 12 separately for each cancer site and sex. When the available information was for less than 15 years, or when data up to 2010 were available, a programme developed at IARC (DEPPRED) based on the simple time-linear prediction models of Dyba and Hakulinen 13 was used to make the short-term predictions. To reduce the prospect of erroneous predictions as a result of inherently large random variation due to small numbers (rare cancers, small populations), cancer-, sex-specific prediction models were fitted only when at least 50 cancer cases or cancer deaths (all ages) were recorded per year for DEPPRED, and when at least 100 cancer cases or deaths (all ages) were recorded per 5-year period for NORDPRED. For the sex and cancer combinations where these criteria were not satisfied, the rates for 2012 were derived from the annual average rates recorded in the most recent 5-year period available. For countries where no historical national incidence or mortality data existed, the most recent disease rates available were used as proxy for 2012. For France, we used the published estimates of national incidence rates for 2011. 14 Since no data were available for Montenegro, incidence and mortality rates were estimated as the simple average of the rates (age-, sex-and sitespecific) of those of Bosnia Herzegovina and Serbia. Random fluctuations in the predicted age-specific incidence and mortality rates were smoothed using a loess function by country, sex and cancer site. The derived age-, sex-and site-specific rates were age-standardised (ASRs per 100,000 person-years) using the European standard population. 15 The number of cancer cases and deaths in 2012 was computed for each country and cancer site by multiplying the predicted 2012 ageand sex-specific incidence and mortality rates by the corresponding 2012 population estimates from the UN Population Division (the 2010 revision). 2 The data sources available for the estimation of the 2012 rates, and the methods applied in the incidence and mortality estimations are summarised in Table 1. 
Mortality
For 38 European countries, cancer mortality data from 1990 to 2010 and corresponding population figures were available through the WHO mortality database. 9 For Bosnia Herzegovina, the data were extracted from the federal cancer registry. 16 For Albania and Macedonia, vital registration is known to be incomplete during the period under study 9 ; the source data were therefore corrected using the estimated percentage of underreporting estimated by the WHO. The changes in the use of ICD in 2000 in France and in 1995 in Switzerland resulted in discontinuity in trends 17, 18 and thus the French and Swiss mortality estimates are derived using short-term predictions based on the period from 2000 using DEPPRED (Table 1) . For Italy and Portugal, mortality data were missing for one or more calendar years in the period [2004] [2005] [2006] , and the nearest available data (generally that of the previous or subsequent year) were replicated to replace the missing values.
There are large variations in the accuracy of death certificates related to cancer of the uterus, with many deaths recorded as "uterus cancer, not otherwise specified" (ICD-10 C55). By default, the cancer deaths coded as "uterus unspecified category" were reallocated to either cervix uteri or corpus uteri cancer according to the observed age-specific proportions of each when the all age proportion of uterine cancer deaths coded to the unspecified category was considered to be low (<25% of the total). 19 For the other countries (Austria, Belgium, France, Germany, Ireland, Italy, Portugal, Slovenia, Sweden and Switzerland) we estimated the all-age proportions of deaths from cervix and corpus uteri cancers using the recorded incidence in local or national cancer registries around 2000 and the corresponding 5-year relative survival probabilities extracted from the EUROCARE 4 study. 20 The total number of cancer deaths from uterine cancers (ICD-10 C53-55) estimated in 2012 were then partitioned into cervix and corpus uteri cancers using the proportions obtained from the survival analysis, and then further stratified by age using age-specific death counts of the two sites extracted from the WHO mortality database. Finally, for the countries with large proportion (more than 25%) of unspecified uterine cancers and no incidence and survival data (Albania, FYR Macedonia, Greece and Luxembourg) we used pooled incidence and survival data from Belgium and France to reallocate the uterine cancer deaths in Luxembourg and a pool from Malta, Slovenia and Portugal was used for the other listed countries. In addition, for Belarus and the Ukraine, the deaths from "corpus uteri and uterus, not otherwise specified" (ICD-10 C54-55) were first partitioned into two components using proportions from the Ukrainian National Cancer Registry mortality data ">" projected to. "!" converted to incidence. "=" applied to. a Corrected for under-reporting. Missing sites: mean average of the estimated mortality rates for Bulgaria and Serbia. b Main category (ICD special list) only. Other category partitioned using mortality data from Ukrainian cancer registry. c Main category (ICD-10 special list) only. Other category partitioned using mortality data from local (Switzerland) or national (Ukraine) cancer registries.
for 2009. 21 The category "uterus cancer, not otherwise specified" was then distributed into the cervix and corpus uteri categories using the age-specific proportions from the same source.
For Belarus, Switzerland and Ukraine, national mortality data for several cancer sites selected for this study were not available. Thus for cancers of the gallbladder, testis, kidney, thyroid as well as Hodgkin lymphoma, the mortality rates from the Ukrainian National Cancer Registry 21 were applied to the national population estimates in Belarus and the Ukraine in 2012, whereas for Switzerland, the rates from the regional Swiss mortality statistics [2004] [2005] [2006] [2007] [2008] 22 were applied to the corresponding population data.
As noted above, projections of national mortality rates were carried out only when a minimum threshold in the number of deaths was recorded per year for a given sex and cancer combination. Otherwise, the mortality rates from the most recent 5-year period were applied to the 2012 population.
Incidence
Recent regional and national (up to 2009) incidence data were extracted from EUREG, part of the ECO website 10 as well as from the NORDCAN database of the Association of Nordic Cancer Registries. 23 National and regional incidence data for other countries were extracted from the Cancer Incidence in Five Continents series 24, 25 and national incidence data for 2009 in Bosnia Herzegovina and Ukraine were extracted from published reports. 16, 21 The methods to estimate the national sex-and age-specific incidence rates in 2012 are summarised in Table 1 and fall into one of the following categories, listed in order of priority:
1. Estimates based on national and local incidence data (27 countries, Table 1 ). 1A. When historical national data and sufficient numbers of recorded cases were available, incidence rates were projected to 2012 using either the NORDPRED or DEPPRED methods. This method for predicting incidence in 2012 was used in 20 countries, and validated for Finland by comparing our estimates to those computed by the Finnish Cancer Registry for the same year. 26 The close agreement between the two sets of estimates is shown in Table 2. 1B. When historical regional incidence data covering at least 30% of a country and sufficient numbers of recorded cases were available (Germany and Switzerland), local incidence rates were projected to 2012 using either NORDPRED or DEPPRED and applied to the 2012 national population. In the absence of such data, the local incidence rates from the most recent available 5-year period were applied to the 2012 national population.
For female breast and prostate cancers, the projection method 1A or 1B could potentially yield unreasonably high values if, for example mammographic screening programmes or PSA testing commenced, respectively, in the calendar period serving as the basis for the estimates. For both cancers, a careful examination of the observed and predicted trends in rates was performed. When the predicted incidence rate for 2012 yielded what was considered by the authors an unrealistically high value, the incidence rate from the most recent 5-year period was applied to the 2012 population (Fig. 1) . Such an adjustment was applied in Austria and Denmark for female breast cancer and in Austria, Belarus, Croatia, Czech Republic, Ireland, Lithuania, Slovakia and the United Kingdom for prostate cancer.
1C. When national incidence rates were available only for a short period of time, the incidence rates for the most recent period available were applied to the 2012 population (five countries, including national estimates for France 14 ).
1. Estimates based on local incidence data and national mortality data (12 countries, Table 1 ).
National incidence (I N ) was estimated by applying a set of sex-, site-and age-specific incidence to corresponding mortality ratios (I R /M R ) obtained from the aggregation of local registries' incidence data, to the corresponding national mortality estimate for 2012 (M N ):
Before aggregation, each registry dataset was weighted according to the square root of its population to take into account the relative size of the population covered. In practice, the I R /M R ratios were obtained from a Poisson regression model, including terms for sex and age. Depending on the accuracy and availability of local data, one of two variants of the method was used, as specified below: 2A. Country-specific models were fitted for three countries (Italy, Poland and Spain) with several local cancer registries in operation: the I R /M R ratios were obtained from the most recent country-specific data (generally a 5-year period centred on year 2005), under the assumption that the I R /M R ratios will be reasonably constant in recent years. This assumption is likely to be violated for female breast and prostate cancers, particularly following the introduction of screening programmes, which may have resulted in marked fluctuation in the ratios of recorded cases to deaths. For these two cancer sites we used the most recent incidence rates from the cancer registries used in the model (generally the year 2007) as a proxy for the 2012 national incidence rate. To achieve a greater stability in the incidence to mortality ratios where the country-specific local data were sparse, additional incidence and mortality data from local cancer registries in neighbouring countries within the same area were included prior to modelling.
2B. Regional models were fitted when no incidence data were available or when they were considered to be lacking sufficient quality (nine countries). The I R / M R ratios were obtained by the aggregation of cancer registry data in neighbouring countries. Specifically for Luxembourg, we applied the age-specific incidence rates (2007) (2008) (2009) ) recorded by the national pathological registry 27 to the national 2012 population where zero cancer deaths were recorded for a particular combination of sex and cancer type. We applied the same redistribution procedure of the number of cancer deaths coded as "uterus unspecified" described above to the local mortality used in the models in methods 2A and 2B. Table 3 and Fig. 2 summarise the estimated numbers of new cancer cases and cancer deaths in Europe in 2012 (in thousands), by type of cancer. There were just over 3.4 million new cases of cancer (excluding non-melanoma skin cancers) in Europe in 2012, 53% (1.8 million) occurring in men and 47% (1.6 million) in women. The most common cancer sites were breast cancer (464,000 cases, 13.5% of all cancer cases), followed by colorectal cancer (447,000, 13.0%), prostate cancer (417,000, 12.1%) and lung cancer (410,000, 11.9%). These four cancers represented half (50.5%) of the estimated overall Table 5 Estimated numbers of new cancer cases and deaths from cancer (thousands), age-standardised rates (ASRs) (per 100,000) by sex and cancer site in the European Union (EU-27) in 2012. Table 4 shows the numbers of new cases and deaths for three most common leading types of cancer in each of the European countries in 2012. Table 5 shows the estimated numbers of cases and deaths by site of cancer and sex (in thousands) for the 27 countries of the European Union (EU-27). The EU-27 accounted for an estimated 2.6 million new cases (76% of the European total) and 1.26 million deaths (72%) in 2012. The most common forms of cancers were breast cancer (364,000 cases, 13.8% of all cancer cases), followed by prostate cancer (360,000, 13.7%), colorectal cancer (342,000, 13.0%) and lung cancer (310,000, 11.8%). These four cancers represented 52% of the overall burden of cancer in the EU-27 in 2012. Lung cancer, with an estimated 265,000 deaths (21.0% of total) was by far the most common cause of death from cancer, followed by colorectal cancer (150,000 deaths, 11.9%), breast cancer (91,000, 7.2%) and pancreatic cancer (78,000, 6.2%).
Results
Tables 6a and 6b show the estimates of incidence and mortality rates by sex and site, for all 40 countries. Tables 7a and 7b portray the estimated numbers of cases and deaths for the same categories. A brief description of the patterns for the four most common cancers in Europe follows.
Overall patterns
After adjusting for differing population age structures, overall incidence rates in both sexes were highest in Northern and Western European countries, in men in France (550 per 100,000) and in women in Denmark (454) (Figs. 3a, b and 4a ). For both male and female, the lowest all-cancer incidence rates were to be found in the Balkan Peninsula with rates almost half in Bosnia HerzSouthern Europe Countries for which no data were available are in italics. C88 + C90 C91-95 C00-96/C44 (Figs. 3c, d and 4b ).
Breast cancer
Breast cancer was the leading cancer site in women in all countries of Europe (Table 4 ) in 2012. There is a 3-fold variation (49-148 per 100,000) with a clear geographical pattern (Fig. 5 ). High incidence rates were estimated in Western European countries, notably in Belgium (147), France (137) and The Netherlands (131) and in Northern Europe, particularly in the United Kingdom (129) and in the Nordic countries, Denmark (143), Iceland (131) and Finland (121). In comparison, incidence rates in Eastern European countries such as the Ukraine (54) and Moldova (53) were much lower. The range of mortality rates varies twofold (15-36 per 100,000). Mortality rates were highest in the North (e.g. Belgium, 29 and Denmark, 28) and in the South (e.g. Serbia, 31 and Macedonia, 36). The high mortality rates in the northern countries reflect the high incidence, while in the south there is a high mortality to incidence ratio, a proxy of unfavourable survival (Fig. 5 ).
Colorectal cancer
The incidence rates of colorectal cancer are slightly higher in men than in women (Fig. 6a) . Elevated rates of incidence were estimated in Central European countries -Slovakia (92 per 100,000), Hungary (87) and Czech Republic (81) in men, and in Norway (54), Denmark (53) and The Netherlands (50) in women. There is up to a fivefold variation in the incidence rates across Europe, with the lowest rates in the Balkan countries of Bosnia Herzegovina (30 in men, 19 in women), Greece (25, 17) and Albania (13, 11) . Geographical patterns of mortality partially follow incidence, although mortality is high also in some countries with relatively low incidence rates (Moldova, Russia, Montenegro, Poland and Lithuania) ( Fig. 6a and 6b) .
Prostate cancer
Incidence rates of prostate cancer vary by more than 7-fold (25-193 per 100,000) the highest rates were estimated in Northern and Western European countries Countries for which no data were available are in italics. C88 + C90 C91-95 C00-96/C44 (30) and Albania (25) . In comparison with incidence, mortality rates vary much less, from the highest estimated rates in Lithuania (36) or Denmark (34) to the lowest in Malta (14) or Albania (13) (Fig. 7) .
Lung cancer
In men, incidence was highest in Central and Eastern European countries -Hungary (109), FYR of Macedonia (102), Serbia (99) and Poland (90) and lowest in the Northern European countries, for example in Finland (45) and Sweden (29) . The reverse was seen in women: elevated rates were estimated in Northern Europe (e.g. Denmark (55) and The Netherlands (44)) and low rates in Eastern Europe (e.g. Ukraine and Belarus (9) or Russian Federation (10)). For both sexes combined the highest rates were seen in Hungary and the lowest in Cyprus (Fig. 8) . Geographical patterns of mortality are quite similar to those of incidence for both sexes (Table 6b ), due to the rapid course of the disease after diagnosis. Lung cancer is the leading cause of cancer death amongst men in all countries except Sweden, and women die from lung cancer more commonly than from breast cancer in a growing number of countries (Table 4 ).
Discussion
This timely and comparative situation analysis of the cancer burden in Europe reveals variations in incidence and mortality rates. These reflect variability in the national health system policies (e.g. organised screening for breast, prostate, cervical and colorectal cancers), the varying prevalence -of risk factors between countries and regions, and disparities in human development and the effective delivery of cancer control measures. Strategies to reduce the extent of the disease burden on the continent evidently need to be established locally, to reflect the profile of the observed cancer rates in each European country and in comparison with the pattern in other countries. We estimated 3.45 million new cases and 1.75 million deaths from cancer in Europe in 2012. In combination, cancers of the female breast, colorectal, prostate and lung represent almost half of the overall burden of cancer in Europe. The same diseases are also major causes of cancer death in Europe in 2012, with stomach and pancreatic cancer ranking 4th and 5th respectively, ahead of prostate cancer.
Since the annual statistics published by cancer registries need 2-5 years to be finalised, the short-term predictions are the best alternative to provide up-to-date figures to timely inform cancer control policies. Additional estimations were required where national incidence data were not available, using incidence and Countries for which no data were available are in italics. C00-14  C15  C16  C18-21  C22  C23-24  C25  C32  C33-34  C43  C50 Countries for which no data were available are in italics.
mortality data from local cancer registries. The methodology is consistent with previous studies estimating cancer incidence and mortality in Europe. 7, 8 Short term prediction methods have been used to prepare estimates for 2012 from the most recently available data -specifically, national mortality rates for the years 2004-2010, and national incidence rates for 2005-2009, depending on the availability of such data in a given country. Although predictions are based on trends in historical data which may or may not continue into the long-term future, they are likely to be reasonably accurate in the short term or when the disease rates exhibit rather stable trends.
In addition to the incompleteness of mortality data, there is also possible underestimation of the cancer mortality in certain European countries where the number of deaths attributed to ill-defined and unknown causes is relatively large (Table 8) . Cancer mortality data are also prone to a lower accuracy (validity) than cancer registry statistics, mainly because of the difficulties in ascertaining and certifying the cause of death. This may have led to an underestimate of the true mortality of cancer at specific sites. Inclusion of metastatic cancers along with primary neoplasms for example amplifies the mortality rates for some sites such as liver, lung and brain. This would inflate the national estimates of mortality and possibly incidence, if the latter relies both on the national mortality statistics and on I R /M R ratios outside the country, as in method 2B. Therefore, some caution must be employed in interpretation of the estimated cancer mortality data. Another attempt to estimate the cancer mortality in the EU-27 for 2012 using a similar methodology was published recently. 28 The overall estimates of 1.28 million cancer deaths (717,000 in men and 566,000 in women) are very close to our estimates of 1.26 million cancer deaths (707,000 in men and 555,000 in women, Table 5 ).
With respect to incidence, several sources of data have been used in generating the statistics. National incidence rates were provided by 24 European countries (Table 1) representing 50% of the total European population. For Germany and Switzerland, the projection of incidence rates based on aggregated local cancer registries data covering a substantial part of the population (30% and 40% respectively, method 1B) was preferred to the "standard" M:I ratio method and the representativeness of the local registry data is of course unknown. The resulting estimates may slightly overestimate or underestimate the incidence rates if the increasing or decreasing trends observed in local registries do not apply to the national population. For 12 countries, itEurope, not only aimed at men, particularly the male populations of Central and Eastern Europe, but increasingly targeted towards young women. Incidence and mortality rates in men are decreasing in many European countries, particularly in Northern and Western areas where the prevalence of smoking amongst men was first to diminish, while the lung cancer rates in Central and Eastern Europe remain high, but are showing signs of stabilisation or decline. 30 Mortality rates in women, who acquired the smoking habit later than men, are largely on the increase in Europe (e.g. France, Spain) although rates are beginning to stabilise, notably in the high-risk countries of Northern Europe. 30 Primary prevention, through efforts to deter the initiation of smoking and raise cessation rates through higher taxes, regulations on smoking and information to the public should have a major impact on incidence and mortality from lung and other tobacco-related cancers, including oral cavity and pharynx, oesophagus, pancreas, larynx and urinary tract. 31 Colorectal cancer is the second most common cause of cancer death in both men and women (Table 4) . Diets low in fruit, vegetables and unrefined plant food, and high in red meat, processed food and fat have been shown to confer an increased risk of colorectal cancer 32 and there is an evidence base to suggest that maintenance of a healthy diet and avoidance of a sedentary lifestyle and obesity may reduce the risk of colorectal cancer. The European Guidelines For Quality Assurance In Colorectal Cancer Screening And Diagnosis indicate there is good evidence that invitation to screening with FOBT using the guaiac test reduces mortality from colorectal cancer by about 15% in average risk populations of appropriate age, and that there is reasonable evidence that flexible sigmoidoscopy screening reduces incidence and mortality if performed within an organised screening programme with strict monitoring of quality and outcomes. 33 Implementation of organised colorectal screening programmes is resource-dependent but is underway in higher-resource countries, and should remain a high priority as a means of early detection of the disease in Europe.
Breast cancer is the leading cancer site in women in all countries in Europe (Table 4) and it is also the first cause of death from cancer in women in Europe (Fig. 2b) . It is likely that the variation observed in breast cancer incidence across European countries (Fig. 5) (e.g. parity, age at first birth(part of the observed differences may be the result of changes in the methodology due to extension of data availability as for Germany and Switzerland), some comparison at the European level with our previous estimates for 2008 8 (3.23 million new cases of cancer and 1.72 million deaths from cancer) could be drawn. The 2012 estimates presented herein show a slight increase in the number of new cases of cancer (in particular for breast and prostate cancers) and a similar estimate of the number of deaths from cancer despite the growth and the ageing of the European population in the period. Therefore, the overall risk of getting cancer in Europe seems to be almost stabilised now although at a high level, while the overall risk of dying from cancer in Europe is declining, with directions of change and magnitude varying by country and by the cancer site. 35 This estimation of cancer incidence in Europe would not be possible without population-based cancer registries functioning in many European countries. The important role of registries in disease surveillance is increasingly being recognised but should not be taken for granted. Cancer registration in Europe is at present facing an uncertain future as a result of funding constraints, inappropriate implementation of e-Health methodology and also because of attempts to implement legislation which would require patients to provide informed consent to permit registration and/or opt-out from registration. 41 The latter restrictions, although intended to safeguard patient confidentiality, have led to concerns that it would no longer be possible to monitor cancer patterns and trends reliably. The inevitable exclusion of an undetermined fraction of cases would introduce serious biases in the data. If European governments consider the control of cancer burden an important issue for the future of Europe, they must commit themselves to an appropriate level of investment in cancer registries and legislation that would safeguard their ability to collect population-based information. Commission (http://cordis.europa.eu/fp7/home_en. html). The estimates and the associated web-site European Cancer Observatory (ECO, http://eco.iarc.fr/) was developed at the International Agency for Research on Cancer (IARC, http://www.iarc.fr) in partnership with the European Network of Cancer Registries (ENCR, http://www.encr.com.fr/). The authors gratefully acknowledged the following cancer registries who contributed to the EUREG database of the ECO web site: Austria -Austrian Cancer Registry, Landes Salzburg Tumour Registry, Tyrol Cancer Registry; Belgium -Belgian Cancer Registry, Flemish Cancer Registry Network; Bulgaria -Bulgarian National Cancer Registry; Croatia -Croatian National Cancer Registry; Cyprus -Cyprus Cancer Registry; Czech RepublicCzech National Cancer Registry; Denmark -Danish Cancer Registry; Estonia -Estonian Cancer Registry; Finland -Finnish Cancer Registry; Germany -Cancer Registry Bavaria, Berlin Cancer Registry, Brandenburg 
